TPST NASDAQ
Tempest Therapeutics, Inc.
1W: -2.1%
1M: -26.2%
3M: -24.2%
YTD: -72.5%
1Y: -92.0%
3Y: -81.7%
5Y: -94.4%
$0.81
+0.01 (+0.63%)
Weekly Expected Move ±39.8%
$0
$0
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
18 relationships18
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-03-29
Earliest Filing
2026-03-23
Latest Filing
partner: 7
acquirer: 4
investor: 3
target: 2
supplier: 2
Counterparties (Filed by TPST)
18 relationshipsCompanies named in TPST's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Factor Bioscience Inc. | — | investor | Strategic investor in private placement securities purchase agreement | 2026-03-23 | View |
| Erigen LLC | — | acquirer | Seller of CAR T-cell therapy assets in exchange for common stock | 2026-02-06 | View |
| Factor Bioscience Inc. | — | acquirer | Seller of CAR T-cell therapy assets in exchange for common stock | 2026-02-06 | View |
| Lotus Capital (BVI) Limited | — | investor | Received common stock as part of the asset acquisition transaction | 2026-02-06 | View |
| Computershare Inc. | — | partner | Warrant Agent for the Warrant Agreement | 2026-02-06 | View |
| Computershare Trust Company, N.A. | — | partner | Warrant Agent for the Warrant Agreement | 2026-02-06 | View |
| Erigen LLC | — | acquirer | Seller of assets including CAR T-cell therapies in exchange for Company Common Stock | 2025-11-19 | View |
| Factor Bioscience Inc. | — | target | Seller of assets including CAR T-cell therapies in exchange for Company Common Stock | 2025-11-19 | View |
| Lotus Capital (BVI) Limited | — | investor | Equity holder of Erigen LLC expected to own 27.0% of the Company post-closing | 2025-11-19 | View |
| F. Hoffmann-La Roche Ltd. | — | supplier | Agreement to supply atezolizumab (TECENTRIQ) for use in the Company's clinical studies. | 2024-10-10 | View |
| Computershare Trust Company, N.A. | — | partner | Serves as rights agent for the Company's Rights Agreement. | 2024-10-10 | View |
| Jefferies LLC | JEF | partner | Sales agent for the Company's open market sale of common stock. | 2024-06-20 | View |
| Computershare Trust Company, N.A. | — | partner | Serves as Rights Agent and transfer agent for the Rights Agreement. | 2023-10-11 | View |
| TempestTX, Inc. | — | partner | Wholly owned subsidiary of Tempest Therapeutics, Inc. | 2022-12-29 | View |
| Millendo Therapeutics US, Inc. | — | partner | Wholly owned subsidiary of Tempest Therapeutics, Inc. | 2022-12-29 | View |
| ARE-San Francisco No. 17, LLC | — | supplier | Landlord providing corporate headquarters lease | 2021-06-28 | View |
| Mars Merger Corp. | — | acquirer | Wholly owned subsidiary of Millendo entering merger with Tempest | 2021-03-29 | View |
| Tempest Therapeutics, Inc. | TPST | target | Target company in merger agreement with Millendo | 2021-03-29 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-28 | Material Agreement; Officer/Director Change; Regulation FD; Exhibits | Agreement | View |
| 2026-09-17 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-09-16 | Shareholder Vote; Other Events | View | |
| 2026-09-15 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-08-24 | Officer/Director Change | View | |
| 2026-08-18 | Shareholder Vote; Other Events | View | |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-08-13 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-07-28 | Shareholder Vote; Other Events | View | |
| 2026-07-22 | Material Agreement; Regulation FD; Exhibits | Agreement | View |
| 2026-06-23 | Shareholder Vote | View | |
| 2026-06-04 | Officer/Director Change; Regulation FD; Exhibits | View | |
| 2026-06-02 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
| 2026-05-29 | Officer/Director Change | View | |
| 2026-05-22 | Officer/Director Change | View | |
| 2026-05-22 | Delisting Notice | View | |
| 2026-05-14 | Earnings Release; Exhibits | View | |
| 2026-05-06 | Regulation FD; Other Events; Exhibits | View | |
| 2026-03-30 | Earnings Release; Exhibits | View | |
| 2026-03-23 | Material Agreement; Unregistered Equity Sales; Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR